RBL1

Across TCGA pan-cancer cohorts, RBL1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated RBL1 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher RBL1 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated RBL1 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, GBM, and LUAD are the cancer types where RBL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	II,III,IV	1.000	0.889	.034	5	view →
GBM	DFS	Median	All	0.211	0.567	.018	3	view →
LUAD	OS	Median	II,III,IV	0.756	1.000	.030	2	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

RBL1–HNSC (DFS)

Open the HNSC breakdown →